Cited by 8Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsBioinformatics and Genomic Networks

Integrative Computational Network Analysis Reveals Site-Specific Mediators of Inflammation in Alzheimer's Disease

Open access
Ravichandran, Srikanth, Michelucci, Alessandro, del Sol, Antonio·2018·Frontiers in Physiology

Abstract

Alzheimer's disease (AD) is a major neurodegenerative disease and is one of the most common cause of dementia in older adults. Among several factors, neuroinflammation is known to play a critical role in the pathogenesis of chronic neurodegenerative diseases. In particular, studies of brains affected by AD show a clear involvement of several inflammatory pathways. Furthermore, depending on the brain regions affected by the disease, the nature and the effect of inflammation can vary. Here, in order to shed more light on distinct and common features of inflammation in different brain regions affected by AD, we employed a computational approach to analyze gene expression data of six site-specific neuronal populations from AD patients. Our network based computational approach is driven by the concept that a sustained inflammatory environment could result in neurotoxicity leading to the disease. Thus, our method aims to infer intracellular signaling pathways/networks that are likely to be constantly activated or inhibited due to persistent inflammatory conditions. The computational analysis identified several inflammatory mediators, such as tumor necrosis factor alpha (TNF-a)-associated pathway, as key upstream receptors/ligands that are likely to transmit sustained inflammatory signals. Further, the analysis revealed that several inflammatory mediators were mainly region specific with few commonalities across different brain regions. Taken together, our results show that our integrative approach aids identification of inflammation-related signaling pathways that could be responsible for the onset or the progression of AD and can be applied to study other neurodegenerative diseases. Furthermore, such computational approaches can enable the translation of clinical omics data toward the development of novel therapeutic strategies for neurodegenerative diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fphys.2018.00154

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • AI-driven network analysis and integrative omics have been employed to identify immune-related molecular signatures and prioritize inflammatory mediators implicated in AD.

    “AI-driven approaches, including network analysis and integrative omics, have been employed to identify immune-related molecular signatures and prioritize inflammatory mediators implicated in AD34,35.”

    From Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions (2025) · cites this paper as [34]

    The Discussion reports that network analysis of AD gene-expression data identified key inflammatory receptors and ligands, supporting the claim about prioritizing inflammatory mediators. The Materials and methods section describes one data type—gene-expression microarrays—and a network algorithm; it does not establish that the study integrated multiple omics types or used an explicitly AI-driven method. The paper identifies inflammation-related signaling networks, but does not clearly describe them as immune-related molecular signatures. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 51

  1. Akiyama H. Barger S. Barnum S. Bradt B. Bauer J. Cole G. M.. (2000). Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383– 421. 10.1016/S0197-4580(00)00124-X 10858586 PMC3887148 · DOI · Paper page
  2. Bailly-Bechet M. Borgs C. Braunstein A. Chayes J. Dagkessamanskaia A. Francois J. M.. (2011). Finding undetected protein associations in cell signaling by belief propagation. Proc. Natl. Acad. Sci. U.S.A. 108, 882– 887. 10.1073/pnas.1004751108 21187432 PMC3021011 · DOI
  3. Blazquez E. Velazquez E. Hurtado-Carneiro V. Ruiz-Albusac J. M. (2014). Insulin in the brain: its pathophysiological implications for States related with central insulin resistance, type 2 diabetes and Alzheimer's disease. Front. Endocrinol. (Lausanne). 5: 161. 10.3389/fendo.2014.00161 25346723 PMC4191295 · DOI
  4. Blesa R. Mohr E. Miletich R. S. Hildebrand K. Sampson M. Chase T. N. (1996). Cerebral metabolic changes in Alzheimer's disease: neurobehavioral patterns. Dementia 7, 239– 245. 10.1159/000106886 8872413 · DOI
  5. Bouras C. Hof P. R. Giannakopoulos P. Michel J. P. Morrison J. H. (1994). Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb. Cortex 4, 138– 150. 10.1093/cercor/4.2.138 8038565 · DOI · Paper page
  6. Brai E. Alina Raio N. Alberi L. (2016). Notch1 hallmarks fibrillary depositions in sporadic Alzheimer's disease. Acta Neuropathol. Commun. 4: 64 10.1186/s40478-016-0327-2 27364742 PMC4929714 · DOI
  7. Canto C. B. Wouterlood F. G. Witter M. P. (2008). What does the anatomical organization of the entorhinal cortex tell us? Neural Plast. 2008: 381243. 10.1155/2008/381243 18769556 PMC2526269 · DOI
  8. Carlo A. S. (2013). Sortilin, a novel APOE receptor implicated in Alzheimer disease. Prion 7, 378– 382. 10.4161/pri.26746 24121631 PMC4134342 · DOI
  9. Carlo A. S. Gustafsen C. Mastrobuoni G. Nielsen M. S. Burgert T. Hartl D.. (2013). The pro-neurotrophin receptor sortilin is a major neuronal apolipoprotein E receptor for catabolism of amyloid-beta peptide in the brain. J. Neurosci. 33, 358– 370. 10.1523/JNEUROSCI.2425-12.2013 23283348 PMC3744345 · DOI
  10. Coulthard M. G. Morgan M. Woodruff T. M. Arumugam T. V. Taylor S. M. Carpenter T. C.. (2012). Eph/Ephrin signaling in injury and inflammation. Am. J. Pathol. 181, 1493– 1503. 10.1016/j.ajpath.2012.06.043 23021982 · DOI
  11. Criscuolo C. Fontebasso V. Middei S. Stazi M. Ammassari-Teule M. Yan S. S.. (2017). Entorhinal cortex dysfunction can be rescued by inhibition of microglial RAGE in an Alzheimer's disease mouse model. Sci. Rep. 7: 42370. 10.1038/srep42370 28205565 PMC5304222 · DOI
  12. Dendrou C. A. McVean G. Fugger L. (2016). Neuroinflammation - using big data to inform clinical practice. Nat. Rev. Neurol. 12, 685– 698. 10.1038/nrneurol.2016.171 27857124 · DOI
  13. Dineley K. T. (2007). Beta-amyloid peptide–nicotinic acetylcholine receptor interaction: the two faces of health and disease. Front. Biosci. 12, 5030– 5038. 10.2741/2445 17569627 · DOI
  14. du Boisgueheneuc F. Levy R. Volle E. Seassau M. Duffau H. Kinkingnehun S.. (2006). Functions of the left superior frontal gyrus in humans: a lesion study. Brain 129, 3315– 3328. 10.1093/brain/awl244 16984899 · DOI
  15. Glass C. K. Saijo K. Winner B. Marchetto M. C. Gage F. H. (2010). Mechanisms underlying inflammation in neurodegeneration. Cell 140, 918– 934. 10.1016/j.cell.2010.02.016 20303880 PMC2873093 · DOI · Paper page
  16. Hasin Y. Seldin M. Lusis A. (2017). Multi-omics approaches to disease. Genome Biol. 18: 83. 10.1186/s13059-017-1215-1 28476144 PMC5418815 · DOI · Paper page
  17. Hou S. T. Callaghan D. Fournier M. C. Hill I. Kang L. Massie B.. (2000). The transcription factor E2F1 modulates apoptosis of neurons. J. Neurochem. 75, 91– 100. 10.1046/j.1471-4159.2000.0750091.x 10854251 · DOI
  18. Jiao S. S. Shen L. L. Zhu C. Bu X. L. Liu Y. H. Liu C. H.. (2016). Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer's disease. Transl. Psychiatry 6: e907. 10.1038/tp.2016.186 27701410 PMC5315549 · DOI
  19. Kiyota T. Ingraham K. L. Jacobsen M. T. Xiong H. Ikezu T. (2011). FGF2 gene transfer restores hippocampal functions in mouse models of Alzheimer's disease and has therapeutic implications for neurocognitive disorders. Proc. Natl. Acad. Sci. U.S.A. 108, E1339– E1348. 10.1073/pnas.1102349108 22042871 PMC3241747 · DOI
  20. Leech R. Sharp D. J. (2014). The role of the posterior cingulate cortex in cognition and disease. Brain 137, 12– 32. 10.1093/brain/awt162 23869106 PMC3891440 · DOI · Paper page
  21. Li M. D. Burns T. C. Morgan A. A. Khatri P. (2014). Integrated multi-cohort transcriptional meta-analysis of neurodegenerative diseases. Acta Neuropathol. Commun. 2: 93. 10.1186/s40478-014-0093-y 25187168 PMC4167139 · DOI
  22. Li P. Nie Y. Yu J. (2015). An effective method to identify shared pathways and common factors among neurodegenerative diseases. PLoS ONE 10: e0143045. 10.1371/journal.pone.0143045 26575483 PMC4648499 · DOI
  23. Liang W. S. Dunckley T. Beach T. G. Grover A. Mastroeni D. Ramsey K.. (2008). Altered neuronal gene expression in brain regions differentially affected by Alzheimer's disease: a reference data set. Physiol. Genomics 33, 240– 256. 10.1152/physiolgenomics.00242.2007 18270320 PMC2826117 · DOI · Paper page
  24. Lin L. Lesnick T. G. Maraganore D. M. Isacson O. (2009). Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics. Trends Neurosci. 32, 142– 149. 10.1016/j.tins.2008.11.006 19162339 PMC2954610 · DOI
  25. May P. (2013). The low-density lipoprotein receptor-related protein 1 in inflammation. Curr. Opin. Lipidol. 24, 134– 137. 10.1097/MOL.0b013e32835e809c 23385651 · DOI · Paper page
  26. McAlpine F. E. Lee J. K. Harms A. S. Ruhn K. A. Blurton-Jones M. Hong J.. (2009). Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol. Dis. 34, 163– 177. 10.1016/j.nbd.2009.01.006 19320056 PMC2948857 · DOI
  27. McAlpine F. E. Tansey M. G. (2008). Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer's disease. J. Inflamm. Res. 1, 29– 39. 10.2147/JIR.S4397 22096345 PMC3218716 · DOI
  28. Mu Y. Gage F. H. (2011). Adult hippocampal neurogenesis and its role in Alzheimer's disease. Mol. Neurodegener. 6: 85. 10.1186/1750-1326-6-85 22192775 PMC3261815 · DOI · Paper page
  29. O'Brien R. J. Wong P. C. (2011). Amyloid precursor protein processing and Alzheimer's disease. Annu. Rev. Neurosci. 34, 185– 204. 10.1146/annurev-neuro-061010-113613 21456963 PMC3174086 · DOI · Paper page
  30. Onitsuka T. Shenton M. E. Salisbury D. F. Dickey C. C. Kasai K. Toner S. K.. (2004). Middle and inferior temporal gyrus gray matter volume abnormalities in chronic schizophrenia: an MRI study. Am. J. Psychiatry 161, 1603– 1611. 10.1176/appi.ajp.161.9.1603 15337650 PMC2793337 · DOI
  31. Pan W. Yu C. Hsuchou H. Zhang Y. Kastin A. J. (2008). Neuroinflammation facilitates LIF entry into brain: role of TNF. Am. J. Physiol. Cell Physiol. 294, C1436– C1442. 10.1152/ajpcell.00489.2007 18385284 PMC2740796 · DOI
  32. Pandey P. Pradhan S. Mittal B. (2008). LRP-associated protein gene (LRPAP1) and susceptibility to degenerative dementia. Genes Brain Behav. 7, 943– 950. 10.1111/j.1601-183X.2008.00436.x 18721259 · DOI
  33. Parish C. R. (2006). The role of heparan sulphate in inflammation. Nat. Rev. Immunol. 6, 633– 643. 10.1038/nri1918 16917509 · DOI
  34. Petro L. S. Paton A. T. Muckli L. (2017). Contextual modulation of primary visual cortex by auditory signals. Philos. Trans. R. Soc. Lond. B Biol. Sci. 372: 20160104. 10.1098/rstb.2016.0104 28044015 PMC5206272 · DOI
  35. Qian M. Shen X. Wang H. (2016). The distinct role of ADAM17 in APP proteolysis and microglial activation related to Alzheimer's Disease. Cell. Mol. Neurobiol. 36, 471– 482. 10.1007/s10571-015-0232-4 26119306 PMC11482503 · DOI
  36. Rajendran R. Giraldo-Velasquez M. Stadelmann C. Berghoff M. (2017). Oligodendroglial fibroblast growth factor receptor 1 gene targeting protects mice from experimental autoimmune encephalomyelitis through ERK/AKT phosphorylation. Brain Pathol. [Epub ahead of print]. 10.1111/bpa.12487 28117910 PMC8028631 · DOI
  37. Ransohoff R. M. (2016). How neuroinflammation contributes to neurodegeneration. Science 353, 777– 783. 10.1126/science.aag2590 27540165 · DOI · Paper page
  38. Ravichandran S. Del Sol A. (2017). Identifying niche-mediated regulatory factors of stem cell phenotypic state: a systems biology approach. FEBS Lett. 591, 560– 569. 10.1002/1873-3468.12559 28094442 PMC5324585 · DOI
  39. Ravichandran S. Okawa S. Martinez Arbas S. Del Sol A. (2016). A systems biology approach to identify niche determinants of cellular phenotypes. Stem Cell Res. 17, 406– 412. 10.1016/j.scr.2016.09.006 27649532 · DOI
  40. Rosenberger A. F. Rozemuller A. J. van der Flier W. M. Scheltens P. van der Vies S. M. Hoozemans J. J. (2014). Altered distribution of the EphA4 kinase in hippocampal brain tissue of patients with Alzheimer's disease correlates with pathology. Acta Neuropathol. Commun. 2: 79. 10.1186/s40478-014-0079-9 25027113 PMC4149234 · DOI
  41. Shanley T. P. Vasi N. Denenberg A. Wong H. R. (2001). The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J. Immunol. 166, 966– 972. 10.4049/jimmunol.166.2.966 11145674 · DOI
  42. Siddiqui S. Fang M. Ni B. Lu D. Martin B. Maudsley S. (2012). Central role of the EGF receptor in neurometabolic aging. Int. J. Endocrinol. 2012: 739428. 10.1155/2012/739428 22754566 PMC3382947 · DOI
  43. Song F. Chiang P. Wang J. Ravits J. Loeb J. A. (2012). Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 71, 104– 115. 10.1097/NEN.0b013e3182423c43 22249457 PMC3270561 · DOI
  44. Stemmer N. Strekalova E. Djogo N. Ploger F. Loers G. Lutz D.. (2013). Generation of amyloid-beta is reduced by the interaction of calreticulin with amyloid precursor protein, presenilin and nicastrin. PLoS ONE 8: e61299. 10.1371/journal.pone.0061299 23585889 PMC3621835 · DOI
  45. Tuncbag N. Braunstein A. Pagnani A. Huang S. S. Chayes J. Borgs C.. (2013). Simultaneous reconstruction of multiple signaling pathways via the prize-collecting steiner forest problem. J. Comput. Biol. 20, 124– 136. 10.1089/cmb.2012.0092 23383998 PMC3576906 · DOI
  46. Turei D. Korcsmaros T. Saez-Rodriguez J. (2016). OmniPath: guidelines and gateway for literature-curated signaling pathway resources. Nat. Methods 13, 966– 967. 10.1038/nmeth.4077 27898060 · DOI
  47. Van Hoesen G. W. Hyman B. T. Damasio A. R. (1991). Entorhinal cortex pathology in Alzheimer's disease. Hippocampus 1, 1– 8. 10.1002/hipo.450010102 1669339 · DOI · Paper page
  48. Woodbury M. E. Ikezu T. (2014). Fibroblast growth factor-2 signaling in neurogenesis and neurodegeneration. J. Neuroimmune Pharmacol. 9, 92– 101. 10.1007/s11481-013-9501-5 24057103 PMC4109802 · DOI · Paper page
  49. Wu G. Feng X. Stein L. (2010). A human functional protein interaction network and its application to cancer data analysis. Genome Biol. 11: R53. 10.1186/gb-2010-11-5-r53 20482850 PMC2898064 · DOI · Paper page
  50. Wyss-Coray T. Rogers J. (2012). Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Cold Spring Harb. Perspect. Med. 2: a006346. 10.1101/cshperspect.a006346 22315714 PMC3253025 · DOI · Paper page
  51. Yuan X. Z. Sun S. Tan C. C. Yu J. T. Tan L. (2017). The role of ADAM10 in Alzheimer's Disease. J. Alzheimers. Dis. 58, 303– 322. 10.3233/JAD-170061 28409746 · DOI

Cited by

Sorted by citations

Authors
Ravichandran, S., Michelucci, A., & del Sol, A.
Affiliations
University of Luxembourg (LU)
Venue
Frontiers in Physiology
Published
2018-03-02
Volume
9
Pages
154-154
ISSN
1664-042X (ISSN-L)
OpenAlex
W2789307638
Cited by
8
References
7
Citations by year
2025: 1 · 2022: 2 · 2021: 3 · 2020: 1 · 2018: 1
FWCI
0.86
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Frontiers in Physiology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Université du Luxembourg
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bioinformatics and Genomic Networks
Keywords
Alzheimer's disease, neuroinflammation, inflammatory mediators, brain region specificity, gene expression networks, signaling pathways, TNF-α, neurotoxicity, neurodegeneration, therapeutic target

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review